| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3866469 | The Journal of Urology | 2010 | 8 Pages |
Abstract
Marker lesion studies are most appropriate for the evaluation of novel anticancer therapeutics. Only patients with multiple recurrent, noninvasive, low grade tumors (intermediate risk) should be recruited. Primary end points should be complete response and recurrence rates after 2 to 3 years.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Ofer N. Gofrit, Kevin C. Zorn, Sergey Shikanov, Gary D. Steinberg,